AstraZeneca Will Use EpiStem's 'Plucked Hair' Technology to Study Biomarkers in Cancer Rx Research | GenomeWeb
NEW YORK (GenomeWeb News) — EpiStem, a UK company focused on developing epithelial stem cells from human hair, said today it has partnered with AstraZeneca to conduct feasibility studies for a biomarker program that may help the drug developer in preclinical and clinical cancer drug studies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.